Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.

Published on Feb 1, 2021in Annals of Oncology32.976
· DOI :10.1016/J.ANNONC.2020.11.013
Raffaella Casolino2
Estimated H-index: 2
(Glas.: University of Glasgow),
Chiara Braconi29
Estimated H-index: 29
(Glas.: University of Glasgow)
+ 8 AuthorsTalia Golan23
Estimated H-index: 23
(Sheba Medical Center)
Sources
Abstract
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalized therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of "all-comer" treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalized treatment allocation has the substantial potential to reduce pancreatic cancer mortality.
📖 Papers frequently viewed together
References106
Newest
#208Jennifer P. Morton (Glas.: University of Glasgow)H-Index: 57
#209Owen J. Sansom (Glas.: University of Glasgow)H-Index: 93
BACKGROUND & AIMS Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. The study aim was to investigate the association between DNA damage response (DDR), replication stress, and novel therapeutic response in PC to develop a biomarker-driven therapeutic strategy targeting DDR and replication stress in PC. METHODS We interrogated the transcriptome, genome, proteome, and fun...
Source
#2Jing Fang (ZJU: Zhejiang University)H-Index: 3
#3Chenhao Tong (ZJU: Zhejiang University)H-Index: 4
Last. Xiujun Cai (ZJU: Zhejiang University)H-Index: 13
view all 8 authors...
BACKGROUND: Pancreatic adenocarcinoma is a highly lethal malignancy. Neoadjuvant chemo(radio)therapy [NAC(R)T] is recommended to use for borderline resectable pancreatic cancer (BRPC) and high-risk resectable pancreatic cancer (RPC), but no high-level evidence exists. METHODS: We searched PubMed, EMBASE, Web of Science, and Cochrane library to identify trials comparing survival data of NAC(R)T with SF for RPC or BRPC. Overall survival (OS) was synthesized in analysis of all the patients (intenti...
Source
#1Shilpa PatilH-Index: 3
#2Benjamin SteuberH-Index: 2
Last. Elisabeth Hessmann (GAU: University of Göttingen)H-Index: 16
view all 21 authors...
Recent studies have thoroughly described genome-wide expression patterns defining molecular subtypes of pancreatic ductal adenocarcinoma (PDAC), with different prognostic and predictive implications. Although the reversible nature of key regulatory transcription circuits defining the two extreme PDAC subtype lineages “classical” and “basal-like” suggests that subtype states are not permanently encoded but underlie a certain degree of plasticity, pharmacologically actionable drivers of PDAC subty...
Source
#1Gianpaolo Balzano (UniSR: Vita-Salute San Raffaele University)H-Index: 45
#2Giovanni Guarneri (UniSR: Vita-Salute San Raffaele University)H-Index: 6
Last. Massimo Falconi (UniSR: Vita-Salute San Raffaele University)H-Index: 106
view all 7 authors...
BACKGROUND The benefits of centralization of pancreatic surgery have been documented, but policy differs between countries. This study aimed to model various centralization criteria for their effect on a nationwide cohort. METHODS Data on all pancreatic resections performed between 2014 and 2016 were obtained from the Italian Ministry of Health. Mortality was assessed for different hospital volume categories and for each individual facility. Observed mortality and risk-standardized mortality rat...
Source
#1Hemant M. Kocher (QMUL: Queen Mary University of London)H-Index: 41
#2Bristi Basu (Cambridge University Hospitals NHS Foundation Trust)H-Index: 22
Last. David Propper (QMUL: Queen Mary University of London)H-Index: 28
view all 21 authors...
Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma (PDAC) growth. Here, in a phase Ib, dose escalation and expansion, trial for patients with advanced, unresectable PDAC (n = 27), ATRA is re-purposed as a stromal-targeting agent in combination with gemcitabine-nab-paclitaxel chemotherapy using a two-step adaptive continual re-assessment method trial design. The maxim...
Source
#2Chenhao Tong (ZJU: Zhejiang University)H-Index: 4
#3Siyuan Fu (ZJU: Zhejiang University)H-Index: 1
Last. Sarun Juengpanich (ZJU: Zhejiang University)H-Index: 8
view all 9 authors...
It has been demonstrated that simultaneous resection of both primary colorectal lesion and metastatic hepatic lesion is a safe approach with low mortality and postoperative complication rates. However, there are some controversies over which kind of surgical approach is better. The aim of study was to compare the efficacy and safety of laparoscopic surgeries and open surgeries for simultaneous resection of colorectal cancer (CRC) and synchronous colorectal liver metastasis (SCRLM). A systemic se...
Source
#1Stephan Dreyer (Glas.: University of Glasgow)H-Index: 11
#2Mark Pinese (Garvan Institute of Medical Research)H-Index: 33
Last. David K. ChangH-Index: 49
view all 36 authors...
Objective: We aimed to define preoperative clinical and molecular characteristics that would allow better patient selection for operative resection. Background: Although we use molecular selection methods for systemic targeted therapies, these principles are not applied to surgical oncology. Improving patient selection is of vital importance for the operative treatment of pancreatic cancer (pancreatic ductal adenocarcinoma). Although surgery is the only chance of long-term survival, 80% still su...
Source
#1Paula Ghaneh (University of Liverpool)H-Index: 62
#2Daniel H. PalmerH-Index: 46
Last. John P. Neoptolemos (University of Liverpool)H-Index: 127
view all 20 authors...
4505Background: Patients with borderline resectable pancreatic cancer have poor survival and low resection rates. Neoadjuvant therapy may improve the outcome for these patients. The aim of this tri...
Source
#1Davendra Sohal (UC: University of Cincinnati)H-Index: 28
#2Mai T. Duong (Fred Hutchinson Cancer Research Center)H-Index: 2
Last. Howard S. Hochster (RU: Rutgers University)H-Index: 66
view all 12 authors...
4504Background: Clinical outcomes after curative treatment of resectable PDA remain suboptimal. To assess the potential of early control of systemic disease with multiagent peri-op CTx, we conducte...
Source
#1Wungki ParkH-Index: 14
#2Jiapeng Chen (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Imane El Dika (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
view all 31 authors...
Purpose: Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response–targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome. Experimental Design: We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombination gene mu...
Source
Cited By6
Newest
#1Atsushi Oba (CU: University of Colorado Boulder)H-Index: 2
#2Marco Del Chiaro (CU: University of Colorado Boulder)H-Index: 34
Last. Itaru Endo (YCU: Yokohama City University)H-Index: 66
view all 21 authors...
The symposium "New criteria of resectability for pancreatic cancer" was held during the 33nd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) in 2021 to discuss the potential modifications that could be made in the current resectability classification. The meeting focused on setting the foundation for developing a new prognosis-based resectability classification that is based on the tumor biology and the response to neoadjuvant treatment (NAT). The symposium included...
Source
#1Yifan Wang (MUHC: McGill University Health Centre)H-Index: 6
#2Bryn Golesworthy (MUHC: McGill University Health Centre)H-Index: 1
Last. Zu-Hua Gao (MUHC: McGill University Health Centre)H-Index: 26
view all 13 authors...
BACKGROUND Traditional medical genetics models are unable to meet the growing demand for germline genetic testing (GT) in patients with exocrine pancreatic cancer (PC). This study investigates the impact of an ambulatory oncology clinic-based GT model. METHODS From 2012 to 2021, patients with PC were prospectively enrolled and considered for GT. Two chronological cohorts were compared: (1) the preuniversal genetic testing (pre-UGT) cohort, which received GT based on clinical criteria or family h...
Source
#1Anna Melissa Schlitter (TUM: Technische Universität München)H-Index: 26
#2Björn Konukiewitz (CAU: University of Kiel)H-Index: 2
Last. Günter Klöppel (TUM: Technische Universität München)H-Index: 54
view all 0 authors...
Das duktale Adenokarzinom ist der dominierende Tumor im Pankreas. Obwohl relativ selten, gehort er wegen seiner schlechten, bislang nur wenig verbesserten Prognose zu den grosen onkologischen Problemen. Fortschritte gab es in der prazisierten Klassifikation und der standardisierten morphologischen Begutachtung. In der aktuellen WHO-Klassifikation werden die seltenen, prognostisch relevanten Subtypen wie das hochmaligne adenosquamose Karzinom oder das niedrigmaligne Kolloidkarzinom deutlich unter...
Source
Malnutrition is a common problem among pancreatic cancer (PC) patients that negatively impacts on their quality of life (QoL) and clinical outcomes. The main objective of this consensus is to address the role of Medical Nutrition Therapy (MNT) into the comprehensive therapeutic management of PC patients. A Spanish multidisciplinary group of specialists from the areas of Medical Oncology; Radiation Oncology; Endocrinology and Nutrition; and General Surgery agreed to assess the role of MNT as part...
Source
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Salvatore PaiellaH-Index: 24
Last. Fieke E.M. Froeling (Glas.: University of Glasgow)H-Index: 17
view all 18 authors...
PURPOSETo analyze the prevalence of homologous recombination deficiency (HRD) in patients with pancreatic ductal adenocarcinoma (PDAC).MATERIALS AND METHODSWe conducted a systematic review and meta...
Source
#1John KokkinosH-Index: 5
#2Anya JensenH-Index: 1
Last. Phoebe A. PhillipsH-Index: 33
view all 7 authors...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and no significant improvement in patient survival has been seen in the past three decades. Treatment options are limited and selection of chemotherapy in the clinic is usually based on the performance status of a patient rather than the biology of their disease. In recent years, research has attempted to unlock a personalised treatment strategy by identifying actionable molecular targets in tumour cells or using preclinic...
Source
#1Greta Carioli (University of Milan)H-Index: 18
#2Matteo Malvezzi (University of Milan)H-Index: 39
Last. Eva Negri (University of Milan)H-Index: 155
view all 7 authors...
Background We predicted cancer mortality statistics for 2021 for the European Union (EU) and its five most populous countries plus the UK. We also focused on pancreatic cancer and female lung cancer. Materials and methods We obtained cancer death certifications and population data from the World Health Organization and Eurostat databases for 1970-2015. We predicted numbers of deaths and age-standardised (world population) rates for 2021 for total cancers and 10 major cancer sites, using a joinpo...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.